Needham Reiterates Buy on Rocket Pharmaceuticals, Maintains $60 Price Target
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Gil Blum reiterates a Buy rating on Rocket Pharmaceuticals (NASDAQ:RCKT) and maintains a $60 price target.
May 23, 2023 | 4:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Gil Blum reiterates a Buy rating on Rocket Pharmaceuticals and maintains a $60 price target.
The news directly mentions Rocket Pharmaceuticals (RCKT) and the Buy rating from Needham analyst Gil Blum. This reaffirmation of the Buy rating and the maintained $60 price target could positively impact RCKT's stock price in the short term as it indicates confidence in the company's performance and potential growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100